The vaccine uses a selected bacterial protein, naturally decorated with small sugar molecules, to trigger an immune response for protection. This approach differs from previous attempts to develop protein-based bacterial vaccines since it involves specific natural sugar modifications previously undiscovered. GlyProVac’s vaccine, GPV02, uses BEMAP technology to imitate E. coli, thus preparing the immune system to recognize the bacteria when an infection occurs.
Current Development Stage: Hit-to-lead
CARB-X Investment: US$467k
Initial CARB-X Investment Date: October 1, 2023